KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells
Disease and Therapeutics
· Elsevier
Аннотация
Publication date: 2026 Source: Disease and Therapeutics, Volume 3 Author(s): Nobuyuki Fujiwara, Ryo Oya, Ryouichi Tsunedomi, Akira Matsuda, Koji Hayakawa, Kosuke Kobayashi, Takashi Ohama
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Медицина»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. // Disease and Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S305099982600023X?dgcid=rss_sd_all
KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. Disease and Therapeutics. https://www.sciencedirect.com/science/article/pii/S305099982600023X?dgcid=rss_sd_all
“KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells.” Disease and Therapeutics.
@article{article43301,
title = {KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells},
journal = {Disease and Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S305099982600023X?dgcid=rss_sd_all}
}